Clinical Experience with Adalimumab in a Multicenter Swiss Cohort of Patients with Crohn’s Disease

Abstract

Background: Controlled clinical trials have demonstrated the efficacy and safety of adalimumab in patients with moderate-to-severe Crohn’s disease (CD), but there is, however, only limited long-term experience with adalimumab in daily practice. Aim: To assess the long-term effectiveness and safety of adalimumab in a multicenter cohort of practice-based patients with moderate-to-severe CD. Methods: We retrospectively reviewed the charts of CD patients who received adalimumab over a 3-year period. Disease severity was scored using the Harvey-Bradshaw index (HBI). Remission was defined as an HBI of ≤4 and response as a reduction in the HBI of >3 points at evaluation compared to the baseline. Univariate logistic regression analysis was used to identify the predictive variables associated with response. Results: The charts of 55 patients were reviewed; remission and response rates observed at weeks 4–6 were 52.7 and 83.6%, respectively. Remission was maintained at weeks 12, 24 and 52 in 89.6, 72.4 and 44.7% of patients, respectively. Remission and response rates were not influenced by smoking status, disease location or duration, the first month total dose, or previous infliximab therapy. The remission rate at weeks 4–6 was significantly higher in patients intolerant of infliximab as compared to those who lost response to this drug. Adalimumab was well tolerated overall. Conclusion: Adalimumab can be considered a suitable option in patients with moderate-to-severe CD, demonstrating sustained long-term effectiveness.

Systematic review with meta‐analysis: the efficacy of a second anti‐TNF in patients with inflammatory bowel disease whose previous anti‐TNF treatment has failed

“…The literature search revealed 797 references in Pubmed and 1067 in Embase; however, some references were excluded, among other reasons, for duplication and non‐availability of data on the effectiveness of the second anti‐TNF . Finally, only 46 studies met the inclusion criteria and were included . Of these, 37 focused on CD (Tables S1 and S2), 8 on UC, and 1 on pouchitis (Table S3).…”

The impact of smoking in Crohn's disease: no smoke without fire

“…Data from adalimumab are limited; the only study so far showed a non-significant but lower response in smokers compared with non-smokers at 4–6 weeks 54. However, there have been concerns over the safety and efficacy of the use of infliximab in smokers.…”

Anti-TNF Therapy Within 2 Years of Crohnʼs Disease Diagnosis Improves Patient Outcomes

“…Similar results have been demonstrated for certolizumab pegol. 17 However, these findings have been disputed by other open label cohort studies that have not demonstrated the same effect of early anti-TNF therapy on clinical response, 18 remission, 19 or dose escalation for secondary loss of response. 20 Furthermore, previous studies have not evaluated whether earlier initiation of anti-TNF therapy alters the long-term surgical risk in CD.…”